Background and Objectives: Increased expression of the CD97, nuclear factor-kB (NF-kB) and cyclooxygenase-2 (COX-2) has been found to play an important role in development of many cancers, including gastric neoplasm. However, the expression and biological behavior of CD97, NF-kB and COX-2 in gastric MALT (mucosa-associated lymphoid tissue) lymphoma has not been well investigated. Methods: The expressions of CD97, COX-2 and NF-kB in 47 cases of gastric MALT lymphoma were detected immunohistochemically, and the relevance between their expressions and the biological behavior was analyzed retrospectively. Results: 1) The expressions of CD97, NF-kB and COX-2 were 87.2%, 36.2% and 48.9%, respectively; 2) The difference of CD97 expression between depth of invasion limited in mucosa and submucosa and beyond muscularis propria was significant (100.0% vs. 71.4%, P < 0.01). Moreover, the expression of nuclear CD97 between stage IIE, III, IV and stage I patients showed significant difference (96.4% vs. 73.7%, P < 0.05); 3) The expression of NF-kB was significantly correlated with tumor size, depth of invasion and stage; 4) The expression of COX-2 was significantly correlated with Helicobacter pylori infection, clinical stage, depth of invasion and tumor size (P < 0.05). Conclusions: Expressions of CD97, NF-κB and COX-2 were correlated with tumor invasion and metastasis in gastric MALT lymphoma.
Isaacson, P. and Wright, D.H. (1983) Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer, 52, 1410-1416. doi:10.1002/1097-0142(19831015)52:8 3.0.CO;2-3
Isaacson, P.G. (2005) Update on MALT lymphomas. Best Practice & Research Clinical Haematology, 18, 57-68. doi:10.1016/j.beha.2004.08.003
Harris, N.L., Jaffe, E.S., Diebold, J., et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
Jaspars, L.H., Vos, W., Aust, G., et al. (2001) Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens, 57, 325-331. doi:10.1034/j.1399-0039.2001.057004325.x
Wang, T., Ward, Y., Tian, L., et al. (2005) CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood, 105, 2836-2844. doi:10.1182/blood-2004-07-2878
Aust, G., Eichler, W., Laue, S., et al. (1997) CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Research, 57, 1798-1806.
Aust, G., Steinert, M., Schutz, A., et al. (2002) CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. American Journal of Clinical Pathology, 118, 699-707. doi:10.1309/A6AB-VF3F-7M88-C0EJ
Galle, J., Sittig, D., Hanisch, I., et al. (2006) Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. American Journal of Pathology, 169, 1802-1811. doi:10.2353/ajpath.2006.060006
Hoang-Vu, C., Bull, K., Schwarz, I., et al. (1999) Regulation of CD97 protein in thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 84, 1104-1109. doi:10.1210/jc.84.3.1104
Liu, Y., Chen, L., Peng, S.Y., et al. (2005) Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. Journal of Zhejiang University Science B, 6, 913-918. doi:10.1631/jzus.2005.B0913
Mustafa T, Klonisch T, Hombach-Klonisch S, et al.: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 2004;24:285-294.
Steinert, M., Wobus, M., Boltze, C., et al. (2002) Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. American Journal of Pathology, 161, 1657-1667. doi:10.1016/S0002-9440(10)64443-4
Wobus, M., Huber, O., Hamann, J. and Aust, G. (2006) CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway. Molecular Carcinogenesis, 45, 881-886. doi:10.1002/mc.20262
Claudio, E., Brown, K., Park, S., et al. (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nature Immunology, 3, 958-965. doi:10.1038/ni842
Fu, L., Lin-Lee, Y.C., Pham, L.V., et al. (2006) Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood, 107, 4540-4548. doi:10.1182/blood-2005-10-4042
Hinz, M., Lemke, P., Anagnostopoulos, I., et al. (2002) Nuclear factor kappaB-dependent gene expression profiling of Hodgkin’s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. Journal of Experimental Medicine, 196, 605-617. doi:10.1084/jem.20020062
Hosokawa, Y. and Seto, M. (2004) Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma. International Journal of Hematology, 80, 215-223. doi:10.1532/IJH97.04101
Jost, P.J. and Ruland, J. (2007) Aberrant NF-kappaB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood, 109, 2700-2707.
Kaisho, T., Takeda, K., Tsujimura, T., et al. (2001) IkappaB kinase alpha is essential for mature B cell development and function. Journal of Experimental Medicine, 193, 417-426. doi:10.1084/jem.193.4.417
Karin, M. and Ben-Neriah, Y. (2000) Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annual Review of Immunology, 18, 621-663. doi:10.1146/annurev.immunol.18.1.621
Ohmae, T., Hirata, Y., Maeda, S., et al. (2005) Helicobacter pylori activates NF-kappaB via the alternative pathway in B lymphocytes. Journal of Immunology, 175, 7162-7169.
Senftleben, U., Cao, Y., Xiao, G., et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293, 1495-1499. doi:10.1126/science.1062677
Souvannavong, V., Saidji, N. and Chaby, R. (2007) Lipopolysaccharide from Salmonella enterica activates NF-kappaB through both classical and alternative pathways in primary B Lymphocytes. Infection and Immunity, 75, 4998-5003. doi:10.1128/IAI.00545-07
Kim, H.J., Hawke, N. and Baldwin, A.S. (2006) NF-kappaB and IKK as therapeutic targets in cancer. Cell Death & Differentiation, 13, 738-747. doi:10.1038/sj.cdd.4401877
Merzianu, M., Jiang, L., Lin, P., et al. (2006) Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and does not correlate with p65 NF-kappaB activation. Modern Pathology, 19, 891-898. doi:10.1038/modpathol.3800609
Pham, L.V., Tamayo, A.T., Yoshimura, L.C., et al. (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. Journal of Immunology, 171, 88-95.
Stoffel, A. (2005) The NF-kappaB signalling pathway: A therapeutic target in lymphoid malignancies? Expert Opinion on Therapeutic Targets, 9, 1045-1061. doi:10.1517/14728222.9.5.1045
Konturek, P.C., Konturek, S.J., Pierzchalski, P., et al. (2001) Cancerogenesis in Helicobacter pylori infected stomach—Role of growth factors, apoptosis and cyclooxygenases. Medical Science Monitor, 7, 1092- 1107.
Hazar, B., Ergin, M., Seyrek, E., et al. (2004) Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leukemia and Lymphoma, 45, 1395-1399. doi:10.1080/10428190310001654032
Paydas, S., Ergin, M., Erdogan, S. and Seydaoglu, G. (2007) Cyclooxygenase-2 expression in non-Hodgkin’s lymphomas. Leukemia and Lymphoma, 48, 389-395. doi:10.1080/10428190601059787
Phipps, R.P., Ryan, E. and Bernstein, S.H. (2004) Inhibition of cyclooxygenase-2: A new targeted therapy for B-cell lymphoma? Leukemia Research, 28, 109-111. doi:10.1016/S0145-2126(03)00260-1
Wun, T., McKnight, H., Tuscano, J.M. (2004) Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma. Leukemia Research, 28, 179-190. doi:10.1016/S0145-2126(03)00183-8
Yamamoto, S., Yamamoto, K., Kurobe, H., et al. (1998) Transcriptional regulation of fatty acid cyclooxygenases-1 and -2. International Journal of Tissue Reactions, 20, 17-22.
Yang, H., Zuo, X., Zhang, K., et al. (2006) Expression of cyclooxygenase-2 and proliferating cell nuclear antigen in gastric mucosa-associated lymphoid tissue lymphoma. World Chinese Journal of Digestology, 12, 1178-1182.
Wu, X., Han, S., Wan, L., et al. (2007) BCL10 and NF-kB are prognostic factors in gastric MALT lymphomas. Chinese Journal of General Surgery, 22,172-175.
Park, S.W., Sung, M.W., Heo, D.S., et al. (2005) Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines. Oncogene, 24, 6689-6698. doi:10.1038/sj.onc.1208816
Wotherspoon, A.C., Doglioni, C., Diss, T.C., et al. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342, 575-577. doi:10.1016/0140-6736(93)91409-F
Sawhney, M., Rohatgi, N., Kaur, J., et al. (2007) Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. International Journal of Cancer, 120, 2545-2556. doi:10.1002/ijc.22657
Yang, G.Z., Li, L., Ding, H.Y., Zhou, J.S. (2005) Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: An immunohistochemical study. Experimental and Molecular Pathology, 79, 214-218. doi:10.1016/j.yexmp.2005.09.002